已酸羟孕酮(Hydroxyprogesterone Caproate) - 药物靶点：PR_在研适应症：子宫内膜异位症，月经紊乱，早产_专利_临床

概要

基本信息

药物类型

小分子化药

别名

17-alpha-hydroxy-progesterone caproate、17alpha-Caproyloxypregn-4-ene-3,20-dione、17alpha-Hydroxyprogesterone hexanoate

+ [21]

靶点

PR

作用机制

PR激动剂(孕激素受体激动剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

Mochida Pharmaceutical Co., Ltd.

非在研机构

AMAG Pharmaceuticals, Inc.Covis Pharma GmbH

Covis Pharma Holdings BV

+ [1]

最高研发阶段批准上市

首次获批日期

美国 (1974-12-26),

早产

最高研发阶段(中国)批准上市

特殊审评加速批准 (美国)、孤儿药 (美国)

登录后查看时间轴

结构

分子式C27H40O4

InChIKeyDOMWKUIIPQCAJU-LJHIYBGHSA-N

CAS号630-56-8

关联

32

项与已酸羟孕酮相关的临床试验

NCT06509074 / Not yet recruiting临床4期IIT

Beta-Blockers in Takotsubo Syndrome Study: A Randomized Clinical Trial (β-Tako)

The Beta-blockers in Takotsubo syndrome (TTS) (β-Tako) trial, is an academic, pragmatic, prospective, multicenter randomized clinical trial, aiming to assess the efficacy of beta-blockers (BB) in TTS patients. Two-hundred patients with TTS will be randomized (1:1) to BB (n=100) or no BB (n=100). BB with alpha or nitric oxide release activity will be used in the treatment arm. The primary endpoint will be the comparison of the wall motion score index by echocardiography at 7 days. A composite clinical endpoint (death, stroke, admission for recurrent TTS, ACS, heart failure or atrial fibrillation) at 1 year, will be assessed by an independent clinical events committee. Several sub-studies will be performed. The β-Tako trial will inform treatment decisions in this uniquely challenging clinical entity.

开始日期2024-08-01

申办/合作机构-

NCT04077853 / Completed临床4期IIT

Efficacy of 17-Hydroxyprogesterone Caproate in Expectantly Managed Early-onset Preeclampsia: A Randomized Controlled Study

Preeclampsia is a disorder of widespread vascular endothelial malfunction and vasospasm that occurs after 20 weeks' gestation and can present as late as 4-6 weeks postpartum

开始日期2019-12-15

申办/合作机构

Assiut University

NCT03779438 / Unknown statusN/AIIT

Intramuscular 17-Alpha-Hydroxyprogesterone Caproate for Prevention of Emergent Cesarean Delivery in Symptomatic Pregnant Women With Placenta Previa: A Randomized Controlled Study

Purpose to evaluate the effects of intramuscular 17-Alpha-Hydroxyprogesterone Caproate (17-OHPC) for prevention of Emergent Cesarean Delivery in symptomatic Pregnant Women with Placenta Previa

开始日期2019-01-01

申办/合作机构-

100 项与已酸羟孕酮相关的临床结果

登录后查看更多信息

100 项与已酸羟孕酮相关的转化医学

登录后查看更多信息

100 项与已酸羟孕酮相关的专利（医药）

登录后查看更多信息

1,267

项与已酸羟孕酮相关的文献（医药）

2024-12-01·PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Developmental 17-OHPC exposure disrupts behavior regulated by the mesocorticolimbic dopaminergic system in rats

Article

作者: Chen, Michael Y. ; Graney, Paige L ; Wagner, Christine K ; Wood, Ruth I ; Wagner, Christine K. ; Wood, Ruth I. ; Chen, Michael Y ; Graney, Paige L.

The synthetic progestin, 17α-hydroxyprogesterone caproate (17-OHPC), is administered to pregnant individuals with the intention of reducing preterm birth. Although there is evidence that 17-OHPC is likely transferred from mother to fetus, there is little information regarding the potential effects of 17-OHPC administration on behavioral and neural development in offspring. Neonatal 17-OHPC exposure disrupts the development of the mesocorticolimbic dopaminergic pathway and associated behaviors in rats. 17-OHPC exposure altered dopaminergic innervation of prelimbic medial prefrontal cortex (mPFC) in neonates and adolescents and altered performance in measures of decision-making, set-shifting, and reversal-learning tasks. The present study tested the effects of developmental 17-OHPC exposure on numerous cognitive behaviors mediated by the mesocorticolimbic dopaminergic system, such as decision-making in a delay discounting task, latent inhibition following conditioned taste aversion (CTA), and spatial memory in the Morris Water Maze (MWM). The present work also aimed to further investigate response omissions in rats exposed to 17-OHPC during development and the potential role of dopamine D2 receptor in altering omissions in a delay discounting task. 17-OHPC exposure rendered rats less sensitive to an Eticlopride-induced increase in omissions in a delay discounting task when compared to controls. Quinpirole flattened the discount curve in both groups but did not significantly affect omissions in 17-OHPC-exposed or control rats. Following CTA, sucrose-pre-exposed 17-OHPC-exposed rats demonstrated decreased latent inhibition when compared to controls. In Morris Water Maze testing, 17-OHPC-exposed rats did not differ from controls after the first day of testing or during probe testing. These results suggest that exposure to 17-OHPC altered aspects of decision-making and latent inhibition in adult male rats, without affecting performance in a measure of spatial learning and memory. Further, the insensitivity of 17-OHPC-exposed males to an Eticlopride-induced increase in omissions suggests a dysfunction in the D2 receptor following exposure to this clinically used synthetic progestin.

2024-10-01·JOURNAL OF MEDICAL PRIMATOLOGY

Characteristics of the Serum Microbiota and Circulating Metabolites in Cynomolgus Monkeys With Spontaneous Type 2 Diabetes Mellitus

Article

作者: Yue, Feng ; Lv, Haizhou ; Tian, Chaoyang ; Yang, Qunhui

ABSTRACT:

Background:

Type 2 diabetes mellitus (T2DM) is widely recognized as a serious global public health concern with a substantial economic burden on patients, their families, and society. Accumulating evidence suggests that an etiologic role for serum microbiota and circulating metabolites in the pathogenesis of T2DM. This study aims to characterize the serum microbiota and circulating metabolites in cynomolgus monkeys with spontaneous T2DM, and provide a reference for the diagnosis and treatment of clinical T2DM.

Methods:

We collected serum samples of the 14 cynomolgus monkeys (15–20 years old, male) for serum microbiota analysis by 16S rRNA gene V3‐V4 region amplicon sequencing and circulating metabolites analysis by ultra‐high‐performance liquid chromatography–tandem mass spectrometry, of which seven were spontaneous T2DM cynomolgus monkeys and seven were healthy controls.

Results:

Our results showed that the serum microbiota abundance and diversity were significantly increased in cynomolgus monkeys with spontaneous T2DM compared to healthy controls, the phyla of Cyanobacteria and Chloroflexi and the genera of Lactobacillus, rhodobacter and collinsella were also significantly increased. A total of 114 serum differentially expressed metabolites (DEMs) were identified, of which 22 were selected as potential biomarkers candidates related to spontaneous T2DM in cynomolgus monkeys by multivariate data analysis. In addition, serum levels of total SCFAs, acetate, butyrate, caproate, isobutyrate, and isovalerate were also significantly increased in the present study. The correlation network analyses have selected certain key DEMs, such as D‐Psicose, 4‐Oxoproline, D‐Glutamine, and Hydroxyphenyllactic acid, which may serve as potential biomarkers for distinguishing between T2DM and healthy controls.

Conclusion:

Our results provide preliminary insights on perturbed serum microbiota and circulating metabolites of cynomolgus monkeys with spontaneous T2DM. These findings would be useful to develop microbiota‐based strategies for T2DM prevention and control.

2024-10-01·FOOD AND CHEMICAL TOXICOLOGY

RIFM fragrance ingredient safety assessment, allyl hexanoate, CAS Registry Number 123-68-2

Review

作者: Dagli, M L ; Ritacco, G ; Burton, G A ; Schultz, T W ; Botelho, D ; Schember, I ; Chon, H ; Lavelle, M ; Lapczynski, A ; Lee, I ; Sullivan, G ; Joshi, K ; Deodhar, C ; Muldoon, J ; Penning, T M ; Cancellieri, M A ; Moustakas, H ; Siddiqi, F ; Bruze, M ; Thakkar, Y ; Belsito, D ; Bryant-Freidrich, A ; Tokura, Y ; Sadekar, N ; Dekant, W ; Farrell, K ; Fryer, A D ; Jones, L ; Sipes, I G ; Bartlett, A ; Api, A M

A review.This review considers available data on the material's phys.-chem. properties, environmental fate (e.g., OECD Guideline biodegradation studies or die-away studies), fish bioaccumulation, and higher-tier model outputs (e.g., US EPA's BIOWIN and BCFBAF found in EPI Suite v4.11).Data on persistence and bioaccumulation are reported below and summarized in the Environmental Safety Assessment section prior to Section I.

110

项与已酸羟孕酮相关的新闻（医药）

2024-10-31

·PRNewswire

Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO® in South Korea

SALT LAKE CITY, Oct. 31, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced a license, development and supply agreement with to SPC Korea granting exclusive rights to market TLANDO® in South Korea. Under the terms of the distribution and license agreement, Lipocine will receive an upfront payment and is also eligible to receive certain regulatory and sales milestone payments, including a payment upon regulatory approval of TLANDO in South Korea. Lipocine is entitled to royalties on net commercial sales. Lipocine will supply TLANDO to SPC Korea and will receive a supply price. SPC Korea will assume responsibility for obtaining regulatory approval within the territory. "We are very pleased to partner TLANDO with SPC Korea," said Dr. Mahesh Patel, President and Chief Executive Officer of Lipocine. "This license agreement represents a strategic opportunity to expand the global reach of TLANDO and to address the significant unmet medical need in South Korea. It underscores Lipocine's commitment to strategic partnerships that have the potential to drive growth and create value for our shareholders while advancing our goals to deliver innovative therapies to patients." About TLANDO TLANDO is approved by the US FDA as a testosterone replacement therapy ("TRT") in adult males indicated for conditions associated with a deficiency or absence of endogenous testosterone: primary hypogonadism (congenital or acquired) and hypogonadotropic hypogonadism (congenital or acquired). It was developed using Lipocine's proprietary Lip'ral drug delivery technology platform. For full prescribing information, please visit . About Lipocine Lipocine is a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery to develop differentiated products. Lipocine has drug candidates in development as well as drug candidates for which we are exploring partnerships. Our drug candidates represent enablement of differentiated, patient friendly oral delivery options for favorable benefit to risk profile which target large addressable markets with significant unmet medical needs. Lipocine's clinical development candidates include: LPCN 1154, oral brexanolone, for the potential treatment of postpartum depression, LPCN 2101 for the potential treatment of epilepsy, LPCN 2203 an oral candidate targeted for the management of essential tremor, LPCN 2401 an oral proprietary combination of anabolic androgen receptor agonist and α-tocopherol, an antioxidant, as an adjunct therapy to incretin mimetics, as an aid for improved body composition in chronic weight management and LPCN 1148, a novel androgen receptor agonist prodrug for oral administration targeted for the management of symptoms associated with liver cirrhosis. Lipocine is exploring partnering opportunities for LPCN 1107, our candidate for prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, LPCN 2401 for chronic weight management, LPCN 1148, for the management of decompensated cirrhosis, and LPCN 1144, our candidate for treatment of non-cirrhotic NASH. TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate developed by Lipocine, is approved by the FDA for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism, in adult males. For more information, please visit . Forward-Looking Statements This release contains "forward-looking statements" that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include statements that are not historical facts regarding our product development efforts, our strategic plans for developing products, our ability to monetize product candidates, including through entering into partnering arrangements, our product candidates and related clinical trials, the achievement of milestones within and completion of clinical trials, the timing and completion of regulatory reviews, outcomes of clinical trials of our product candidates, and the potential uses and benefits of our product candidates. Investors are cautioned that all such forward-looking statements involve risks and uncertainties, including, without limitation, the risks that we may not be successful in developing product candidates, we may not have sufficient capital to complete the development processes for our product candidates, we may not be able to enter into partnerships or other strategic relationships to monetize our non-core assets, the FDA will not approve any of our products, risks related to our products, expected product benefits not being realized, clinical and regulatory expectations and plans not being realized, new regulatory developments and requirements, risks related to the FDA approval process including the receipt of regulatory approvals, and our ability to utilize a streamlined approval pathway for LPCN 1154, the results and timing of clinical trials, patient acceptance of Lipocine's products, the manufacturing and commercialization of Lipocine's products, and other risks detailed in Lipocine's filings with the SEC, including, without limitation, its Form 10-K and other reports on Forms 8-K and 10-Q, all of which can be obtained on the SEC website at . Lipocine assumes no obligation to update or revise publicly any forward-looking statements contained in this release, except as required by law. SOURCE Lipocine Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

引进/卖出上市批准

2024-10-02

·PRNewswire

Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024

SALT LAKE CITY, Oct. 2, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced that it will host a virtual key opinion leader (KOL) event on LPCN 2401 for improved body composition in obesity management on Wednesday, October 16, 2024 at 11:00 am ET. To register, click here. The event will feature Frank Greenway, MD (Professor and Chief Medical Officer at Pennington Biomedical Research Center), who will discuss the unmet needs and current treatment landscape in obesity management with a focus on fat loss and lean muscle mass preservation for patients on incretin therapies. The event will also review positive data from the Phase 2 study of LPCN 2401, comprised of an oral proprietary androgen receptor agonist, which showed significant improvements in body composition. The data support the potential for LPCN 2401 to be used as an adjunct with incretin mimetics (GLP-1/GIP agonists) or as a monotherapy, including post incretin mimetic discontinuation. A live question and answer session will follow the formal presentation. About LPCN 2401 LPCN 2401 is an oral formulation comprised of a proprietary anabolic androgen receptor agonist targeted for once daily regimen. Data from preclinical and clinical studies support the potential of LPCN 2401 in preserving lean mass while reducing fat mass (preferentially VAT and android fat) and beneficial liver and bone health effects. As adjunct therapy to incretin mimetics, LPCN 2401 has potential to amplify GLP-1 action, ameliorate loss of muscle mass, improve muscle quality and functionality, and amplify fat mass loss with improved body composition, with no overlapping GI side effects. Moreover, post incretin mimetic discontinuation, LPCN 2401 has potential to attenuate weight gain, prevent "fat overshoot," and accelerate lean mass rebound. About Lipocine Lipocine is a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery to develop differentiated products. Lipocine has drug candidates in development as well as drug candidates for which we are exploring partnerships. Our drug candidates represent enablement of differentiated, patient friendly oral delivery options for favorable benefit to risk profile which target large addressable markets with significant unmet medical needs. Lipocine's clinical development candidates include: LPCN 1154, oral brexanolone, for the potential treatment of postpartum depression; LPCN 2101, for the potential treatment of epilepsy; LPCN 2203, an oral candidate targeted for the management of essential tremor; LPCN 2401, comprised of an oral proprietary anabolic androgen receptor agonist, as an adjunct therapy to incretin mimetics as an aid for improved body composition in chronic weight management; and LPCN 1148, a novel androgen receptor agonist prodrug for oral administration targeted for the management of symptoms associated with liver cirrhosis. Lipocine is exploring partnering opportunities for LPCN 1107, our candidate for prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, LPCN 2401 for chronic weight management, LPCN 1148 for the management of decompensated cirrhosis, and LPCN 1144, our candidate for treatment of non-cirrhotic NASH. TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate developed by Lipocine, is approved by the FDA for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism, in adult males. For more information, please visit . Forward-Looking Statements This release contains "forward-looking statements" that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include statements that are not historical facts regarding our product development efforts, our strategic plans for developing products, our ability to monetize product candidates, including through entering into partnering arrangements, our product candidates and related clinical trials, the achievement of milestones within and completion of clinical trials, the timing and completion of regulatory reviews, outcomes of clinical trials of our product candidates, and the potential uses and benefits of our product candidates. Investors are cautioned that all such forward-looking statements involve risks and uncertainties, including, without limitation, the risks that we may not be successful in developing product candidates, we may not have sufficient capital to complete the development processes for our product candidates, we may not be able to enter into partnerships or other strategic relationships to monetize our non-core assets, the FDA will not approve any of our products, risks related to our products, expected product benefits not being realized, clinical and regulatory expectations and plans not being realized, new regulatory developments and requirements, risks related to the FDA approval process including the receipt of regulatory approvals, and our ability to utilize a streamlined approval pathway for LPCN 1154, the results and timing of clinical trials, patient acceptance of Lipocine's products, the manufacturing and commercialization of Lipocine's products, and other risks detailed in Lipocine's filings with the SEC, including, without limitation, its Form 10-K and other reports on Forms 8-K and 10-Q, all of which can be obtained on the SEC website at . Lipocine assumes no obligation to update or revise publicly any forward-looking statements contained in this release, except as required by law. SOURCE Lipocine Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床2期临床结果上市批准

2024-09-14

·药事纵横

BridgeBio：终止一项AAV基因疗法临床试验

声明：因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及）;本文不构成任何投资建议。 2024年9月10日，专注于遗传性疾病的BridgeBio Pharma宣布了公司在研的AAV5基因疗法BBP-631用于治疗先天性肾上腺皮质增生症（CAH）的1/2期开放标签ADventure研究的初步结果。鉴于试验结果未达到目前需要追加资本投资的门槛，公司表示将不会继续推进该试验，此外将继续监测于2021年开始的这项研究中的八名入组患者，目前没有与治疗相关的严重不良事件报告。这项1/2期开放标签ADventure研究旨在评估BBP-631在典型CAH成人患者中的安全性、耐受性和药效学活性。迄今为止，该研究的主要结果包括：所有患者在服用较大剂量时，内源性皮质醇分泌均有所增加。在两个最高剂量水平的ACTH刺激试验后，与基线相比的最大变化分别为4.7 μg/dL 和 6.6 μg/dL，皮质醇水平高达11μg/dL。 11-脱氧皮质醇（21-羟化酶的产物）的大量持久增加和17-羟孕酮（17-OHP）（21-羟化酶的底物）的减少为BBP-631转基因的持久活性提供了令人信服的证据：在最高剂量水平，持续的11-脱氧皮质醇与基线相比平均增加了55倍，与基线相比最大增加了99倍。这意味着平均最大值是正常值上限的23倍。17-羟孕酮大幅降低，大多数患者的降幅≥50%，最大降幅达95%。 BBP-631 的耐受性良好，仅有轻度至中度的治疗突发不良事件 (TEAE)，未报告与治疗相关的 SAE。 BridgeBio首席执行官兼创始人Neil Kumar博士说：“虽然迄今为止的数据还不能说明问题，但这项研究首次表明，CAH 患者确实可以自己制造皮质醇，而且基因疗法可以在这一患者群体中安全应用。我们将继续致力于为 CAH 群体寻找合适的合作伙伴，并对预筛选研究和 ADventure 研究的参与者和表示有兴趣的人表示感谢。我们还要感谢ADventure研究的调查人员和工作人员、CAH患者权益组织以及更广泛的CAH社区。" BridgeBio首席财务官、特许金融分析师、博士Brian Stephenson表示："鉴于试验结果未达到目前需要追加资本投资的门槛，BridgeBio将按照我们的资本分配原则，削减基因疗法预算超过5000万美元，并将基因疗法保留给我们无法以其他方式治疗的优先靶点。我们相信基因疗法有可能满足尚未得到满足的巨大需求，我们渴望与 FDA 和卡纳文社区密切合作，目标是尽快将我们的疗法带给卡纳文病患者家庭。” BridgeBio将不再致力于开发BBP-631用于治疗CAH ，但公司仍在积极寻求合作机会，以支持 BBP-631或用于治疗CAH 的下一代基因疗法的未来开发。该公司2个产品已处于商业化阶段，目前有8条研发管线，包括Acoramidis在内的3个候选产品处于3期临床试验阶段。 BridgeBio公司目前的主要工作是为其转甲状腺素蛋白淀粉样变性心肌病（ATTR-CM）药物acoramidis可能获得批准做准备，美国FDA将于11月29日对该药物做出决定。Acoramidis是一种口服、强效、高选择性小分子转甲状腺素蛋白（TTR）稳定剂，用于治疗ATTR-CM。BridgeBio已授予拜耳（Bayer）公司在欧洲商业化acoramidis用于治疗ATTR-CM的独家权利。 Acoramidis作用机制（图片来源：公司官网）公司管线中还有一款用于治疗卡纳万病的在研静脉注射（IV）AAV9基因疗法BBP-812。2024年9月10日，BridgeBio Pharma宣布美国FDA已授予BBP-812再生医学高级疗法（RMAT）称号，RMAT指定是在美国FDA对研究BBP-812的CANaspire 1/2期临床试验的临床数据进行审查后授予的，BBP-812是一种潜在的疗法，可满足卡纳万病患者尚未得到满足的医疗需求。据联邦试验数据库显示，BridgeBio的子公司Aspa Therapeutics正在一项1/2期开放标签研究中测试这种代号为BBP-812的疗法，该研究将于2026年10月结束。图片来源：https://clinicaltrials.gov 此外，BridgeBio正与National Resilience合作，生产候选药物及其管线中的其他基因疗法。BridgeBio公司也表示目前正在 “积极寻求合作机会”，以开发基因疗法或治疗遗传病的潜在后续候选药物。该公司称，CAH影响着美国和欧盟约75,000人。参考资料：公司公告

基因疗法临床研究临床结果

100 项与已酸羟孕酮相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00949	已酸羟孕酮	G03DA03	DB06789

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
子宫内膜异位症	中国	华中药业股份有限公司	1981-01-01
月经紊乱	中国	华中药业股份有限公司	1981-01-01
子宫出血	中国	华中药业股份有限公司	1981-01-01
习惯性流产	日本	Mochida Pharmaceutical Co., Ltd.	1975-06-26
先兆流产	日本	Mochida Pharmaceutical Co., Ltd.	1975-06-26
闭经	日本	Mochida Pharmaceutical Co., Ltd.	1975-06-26
不孕	日本	Mochida Pharmaceutical Co., Ltd.	1975-06-26
子宫不规则出血	日本	Mochida Pharmaceutical Co., Ltd.	1975-06-26
早产	美国	Allergan Sales LLC	1974-12-26

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
HIV感染	临床3期	赞比亚	AMAG Pharmaceuticals, Inc.	2018-02-07
疼痛	临床3期	美国	AMAG Pharmaceuticals, Inc.	2016-10-07

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03292731 (Pubmed)	临床1/2期	早产 17-hydroxyprogesterone caproate	-	17-hydroxyprogesterone caproate 250mg	窪齋鬱觸積簾願積齋鹽(衊膚製鬱壓夢製鑰鹹遞) = 鬱簾觸廠遞糧製顧顧製壓築遞範範積衊獵鏇膚 (夢鹽願鑰襯積鏇淵壓鹹 )	-	2023-07-01
				17-hydroxyprogesterone caproate 500mg	窪齋鬱觸積簾願積齋鹽(衊膚製鬱壓夢製鑰鹹遞) = 顧構製壓鹽醖願鏇繭觸壓築遞範範積衊獵鏇膚 (夢鹽願鑰襯積鏇淵壓鹹 )
NCT03433040 (CTgov)	临床3期	肥胖 \| 早产	44	17-Hydroxyprogesterone Capronate (Non Obese)	鹽鏇選繭顧醖窪廠範窪(顧艱艱簾鹽醖網醖襯鹹) = 遞鏇醖繭艱積鬱鹹網淵網夢願蓋糧繭鑰範築艱 (醖獵獵膚鬱壓膚襯醖廠, 齋鹽鏇遞夢願構膚壓簾 ~ 鹽餘衊獵齋窪膚夢鹹鬱) 更多	-	2022-01-12
				17-Hydroxyprogesterone Capronate (Obese - Control)	鹽鏇選繭顧醖窪廠範窪(顧艱艱簾鹽醖網醖襯鹹) = 糧鹹觸衊艱鹹憲壓顧構網夢願蓋糧繭鑰範築艱 (醖獵獵膚鬱壓膚襯醖廠, 夢壓鏇積簾範壓壓膚遞 ~ 製鹽繭顧範構糧襯膚觸) 更多
NCT03297216 (Pubmed) 人工标引	临床3期	HIV感染 \| 早产	800	Hydroxyprogesterone Caproate	衊襯鬱願衊鹹膚選鏇範(艱網鏇遞鹽糧窪顧顧顧) = 窪糧衊範襯網憲築顧鑰醖襯壓衊積網襯顧築衊 (壓遞鹽夢遞糧淵蓋鑰壓 )	不佳	2021-10-01
				Placebo	衊襯鬱願衊鹹膚選鏇範(艱網鏇遞鹽糧窪顧顧顧) = 製鏇糧製艱壓獵範鹽築醖襯壓衊積網襯顧築衊 (壓遞鹽夢遞糧淵蓋鑰壓 )
NCT03297216 (IPOP, CTgov)	临床3期	HIV感染 \| 早产	800	17P (250 mg 17P)	鹹壓鹹簾餘蓋鬱艱繭鹽(積廠鑰鑰鑰範餘醖選衊) = 衊窪遞選繭築鬱選夢餘鑰餘夢夢夢鑰憲壓鏇鹹 (壓餘網鬱蓋淵築繭鏇廠, 鏇顧膚獵壓鹽繭網憲構 ~ 積範鹽製膚選膚艱蓋廠) 更多	-	2021-07-09
				Placebo (Placebo)	鹹壓鹹簾餘蓋鬱艱繭鹽(積廠鑰鑰鑰範餘醖選衊) = 選鬱糧鹽淵積廠糧廠淵鑰餘夢夢夢鑰憲壓鏇鹹 (壓餘網鬱蓋淵築繭鏇廠, 齋蓋觸顧觸網鏇觸願鬱 ~ 觸網膚鏇簾膚觸壓鑰遞) 更多
NCT01004029 (PROLONG, CTgov)	临床3期	早产	1,740	Vehicle	鑰鏇醖襯糧鏇壓選築鬱(夢積衊廠簾鏇獵積鹽襯) = 憲觸餘糧憲糧憲窪觸築範觸襯夢窪遞膚齋鏇鹽 (鑰繭顧構範遞構遞膚廠, 衊糧鏇鹽網簾鹹簾選衊 ~ 積糧鏇選壓觸選製繭膚) 更多	-	2021-01-28
NCT01004029 (PROLONG, Pubmed \| Am J Perinatol) 人工标引	临床3期	早产	1,708	17-α-hydroxyprogesterone caproate or	製壓繭齋憲願網繭遞繭(簾衊鬱鏇窪夢積選積鏇) = 願選獵齋顧鹹獵鏇鹹鬱積鏇憲齋繭艱艱簾鬱鏇 (觸選簾壓簾範艱鬱淵願 ) 更多	不佳	2020-01-01
				Placebo	製壓繭齋憲願網繭遞繭(簾衊鬱鏇窪夢積選積鏇) = 醖淵觸憲齋積鏇蓋艱簾積鏇憲齋繭艱艱簾鬱鏇 (觸選簾壓簾範艱鬱淵願 ) 更多
NCT00439374 (SCAN, CTgov)	临床3期	早产	657	17 alpha-hydroxyprogesterone caproate (17 Alpha-hydroxyprogesterone Caproate)	憲壓願鬱壓餘觸構鏇鬱(範簾製襯積鹽鹽糧範膚) = 製簾積醖齋積簾淵製蓋遞壓顧簾繭憲繭襯醖繭 (壓夢網觸廠繭窪繭鏇艱, 獵遞鏇夢憲網鏇鑰築鑰 ~ 淵鏇範顧膚憲廠壓夢壓) 更多	-	2019-04-11
				Placebo Oil (Placebo)	憲壓願鬱壓餘觸構鏇鬱(範簾製襯積鹽鹽糧範膚) = 鬱鏇顧餘糧遞願網築鏇遞壓顧簾繭憲繭襯醖繭 (壓夢網觸廠繭窪繭鏇艱, 糧鬱範夢觸遞廠衊顧願 ~ 獵夢獵蓋膚構齋衊襯獵) 更多
NCT02937766 (CTgov)	临床3期	疼痛	60	Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) (Treatment A)	齋襯築壓淵積繭鏇蓋夢(廠鏇鏇膚膚夢淵觸製築) = 觸襯繭構壓築壓觸淵網觸夢鹽鑰鬱選選窪齋構 (膚鑰鑰衊餘願選製醖艱, 遞襯糧網艱簾艱範蓋壓 ~ 觸蓋壓鏇艱願淵鏇蓋觸) 更多	-	2018-12-12
				Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) (Treatment B)	齋襯築壓淵積繭鏇蓋夢(廠鏇鏇膚膚夢淵觸製築) = 蓋顧鹽觸齋糧繭構鏇鹹觸夢鹽鑰鬱選選窪齋構 (膚鑰鑰衊餘願選製醖艱, 糧壓觸艱糧醖範壓顧構 ~ 範鏇淵網衊築製鏇鹽構) 更多
NCT02940522 (CTgov)	临床1期	-	122	Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) (Treatment A)	製製築夢鹽選衊壓壓襯(膚齋襯襯蓋獵鬱醖鑰淵) = 積鏇襯糧膚窪築觸衊蓋獵鏇糧餘觸鑰齋衊鹽觸 (製繭願鹹襯積窪積膚廠, 蓋淵壓網糧觸積壓顧襯 ~ 蓋鏇襯廠艱膚網窪鹽膚) 更多	-	2018-11-30
				Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) (Treatment B)	製製築夢鹽選衊壓壓襯(膚齋襯襯蓋獵鬱醖鑰淵) = 選製齋構餘壓餘鹽鑰鏇獵鏇糧餘觸鑰齋衊鹽觸 (製繭願鹹襯積窪積膚廠, 鹽築壓膚艱窪淵憲壓鏇 ~ 艱鑰簾選網構艱願鹹膚) 更多